Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Emerging drugs for diabetic macular edema: an update. Local targets link to admitted publications; unresolved targets remain external evidence.
10.2337/dc26-s001
10.2337/dc26-s001 · External reference
10.1001/jamaophthalmol.2023.2289
10.1001/jamaophthalmol.2023.2289 · External reference
10.1056/nejmra1909637
10.1056/nejmra1909637 · External reference
10.1097/iae.0000000000001555
10.1097/iae.0000000000001555 · External reference
10.1056/nejm199412013312203
10.1056/nejm199412013312203 · External reference
10.1016/s2213-8587(16)30052-3
10.1016/s2213-8587(16)30052-3 · External reference
10.1111/aos.14891
10.1111/aos.14891 · External reference
10.2337/db15-0317
10.2337/db15-0317 · External reference
10.1038/s41433-020-01377-x
10.1038/s41433-020-01377-x · External reference
10.1167/iovs.10-6386
10.1167/iovs.10-6386 · External reference
10.1016/j.oret.2025.06.014
10.1016/j.oret.2025.06.014 · External reference
10.1016/j.preteyeres.2021.100940
10.1016/j.preteyeres.2021.100940 · External reference
10.3389/fimmu.2020.00154
10.3389/fimmu.2020.00154 · External reference
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment
10.1080/13543784.2020.1723078 · 2020 · External reference
10.1016/j.ophtha.2011.12.039
10.1016/j.ophtha.2011.12.039 · External reference
10.1016/j.ophtha.2013.02.034
10.1016/j.ophtha.2013.02.034 · External reference
10.1016/j.ophtha.2014.05.006
10.1016/j.ophtha.2014.05.006 · External reference
10.1016/j.ophtha.2016.07.032
10.1016/j.ophtha.2016.07.032 · External reference
10.1016/j.oret.2024.05.017
10.1016/j.oret.2024.05.017 · External reference
10.1016/j.preteyeres.2023.101219
10.1016/j.preteyeres.2023.101219 · External reference
10.1016/j.survophthal.2025.08.017
10.1016/j.survophthal.2025.08.017 · External reference
10.1186/s13643-023-02261-x
10.1186/s13643-023-02261-x · External reference
Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the pagoda randomized clinical trial
10.1001/jamaophthalmol.2025.0006 · 2025 · External reference
10.1016/j.ophtha.2023.02.024
10.1016/j.ophtha.2023.02.024 · External reference
10.1016/j.ophtha.2021.09.016
10.1016/j.ophtha.2021.09.016 · External reference
10.1016/j.ophtha.2024.12.018
10.1016/j.ophtha.2024.12.018 · External reference
10.1001/jamaophthalmol.2017.6565
10.1001/jamaophthalmol.2017.6565 · External reference
10.1038/s41433-019-0606-9
10.1038/s41433-019-0606-9 · External reference
10.1001/jamaophthalmol.2019.1963
10.1001/jamaophthalmol.2019.1963 · External reference
10.1038/s41433-019-0522-z
10.1038/s41433-019-0522-z · External reference
10.1016/j.ajo.2021.06.030
10.1016/j.ajo.2021.06.030 · External reference
10.1002/14651858.cd007419.pub7
10.1002/14651858.cd007419.pub7 · External reference
10.1001/jamaophthalmol.2017.4914
10.1001/jamaophthalmol.2017.4914 · External reference
Outcomes of eyes with persistent diabetic macular oedema: the Fight Retinal Blindness!
2026 · External reference
Visual outcomes after early dexamethasone implant in patients with diabetic macular edema compared to standard of Care: ERLYDEX study
2025 · External reference
10.3389/fmed.2026.1761325
10.3389/fmed.2026.1761325 · External reference
10.1136/bjo-2024-326006
10.1136/bjo-2024-326006 · External reference
Unresolved reference
External reference
10.1016/j.exer.2019.107823
10.1016/j.exer.2019.107823 · External reference
10.1016/s1470-2045(25)00350-x
10.1016/s1470-2045(25)00350-x · External reference
Unresolved reference
External reference
Phase 1 study of ASKG712 (anti-VEGF-A/Ang-2 bispecific antibody) for diabetic macular edema (DME)
2025 · External reference
10.1016/s0140-6736(22)00018-6
10.1016/s0140-6736(22)00018-6 · External reference
10.1016/j.ophtha.2023.12.026
10.1016/j.ophtha.2023.12.026 · External reference
Unresolved reference
External reference
10.1016/j.preteyeres.2021.100966
10.1016/j.preteyeres.2021.100966 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1001/jamaophthalmol.2026.0610
10.1001/jamaophthalmol.2026.0610 · External reference
Unresolved reference
External reference
10.1126/scitranslmed.abj2177
10.1126/scitranslmed.abj2177 · External reference
Unresolved reference
External reference
10.1016/s0140-6736(23)01520-9
10.1016/s0140-6736(23)01520-9 · External reference
10.1016/s0140-6736(23)01583-0
10.1016/s0140-6736(23)01583-0 · External reference
10.1016/j.ophtha.2025.12.011
10.1016/j.ophtha.2025.12.011 · External reference
10.1371/journal.pone.0335390
10.1371/journal.pone.0335390 · External reference
10.1001/jama.2022.25029
10.1001/jama.2022.25029 · External reference
10.1001/jamaophthalmol.2021.2809
10.1001/jamaophthalmol.2021.2809 · External reference
10.1074/jbc.ra119.011273
10.1074/jbc.ra119.011273 · External reference
10.1126/sciadv.aba7457
10.1126/sciadv.aba7457 · External reference
Unresolved reference
External reference
10.1016/j.preteyeres.2018.11.008
10.1016/j.preteyeres.2018.11.008 · External reference
10.1371/journal.pone.0243497
10.1371/journal.pone.0243497 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/s41591-024-02802-4
10.1038/s41591-024-02802-4 · External reference
Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition
10.1016/j.cmet.2021.01.011 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1056/evidoa2400009
10.1056/evidoa2400009 · External reference
Safety and efficacy of senolytic candidate UBX1325 for diabetic macular edema: the behold Phase 2 and aspire Phase 2b trials
2025 · External reference
10.1016/j.preteyeres.2017.06.001
10.1016/j.preteyeres.2017.06.001 · External reference
10.1007/s00011-016-1002-6
10.1007/s00011-016-1002-6 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1016/j.xops.2026.101167
10.1016/j.xops.2026.101167 · External reference
Unresolved reference
External reference
10.1001/jamaophthalmol.2019.6035
10.1001/jamaophthalmol.2019.6035 · External reference
10.1016/j.ajo.2025.06.010
10.1016/j.ajo.2025.06.010 · External reference
10.1080/20415990.2024.2406226
10.1080/20415990.2024.2406226 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1158/1078-0432.ccr-21-2334
10.1158/1078-0432.ccr-21-2334 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1002/14651858.cd011599.pub2
10.1002/14651858.cd011599.pub2 · External reference
10.3390/jcm13051327
10.3390/jcm13051327 · External reference
10.4103/tjo.tjo_68_19
10.4103/tjo.tjo_68_19 · External reference
10.1016/j.clinthera.2022.11.003
10.1016/j.clinthera.2022.11.003 · External reference
10.1111/aos.14861
10.1111/aos.14861 · External reference
10.1111/aos.15215
10.1111/aos.15215 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with noninfectious uveitis: an in-depth look at efficacy and safety
2023 · External reference
Uveitis in adults: a review
10.1001/jama.2025.4358 · 2025 · External reference
Unresolved reference
External reference
10.3390/jcm14093205
10.3390/jcm14093205 · External reference
FDA documents reveal the value of a costly gene therapy
10.1016/j.drudis.2019.01.019 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
2021 · External reference
Unresolved reference
External reference
10.1167/iovs.65.14.1
10.1167/iovs.65.14.1 · External reference
Unresolved reference
External reference
10.1016/s0140-6736(24)00310-6
10.1016/s0140-6736(24)00310-6 · External reference
Unresolved reference
External reference
10.1089/jop.2019.0126
10.1089/jop.2019.0126 · External reference
10.2147/opth.s364200
10.2147/opth.s364200 · External reference
Unresolved reference
External reference
Interim results for Phase I study of intravitreal gene therapy FT-003 in patients with diabetic macular edema (DME)
2025 · External reference
10.1002/14651858.cd016315
10.1002/14651858.cd016315 · External reference
10.1097/iae.0000000000004167
10.1097/iae.0000000000004167 · External reference
10.1167/iovs.17-23042
10.1167/iovs.17-23042 · External reference
10.1038/s41598-020-64332-6
10.1038/s41598-020-64332-6 · External reference
10.1001/jamaophthalmol.2021.0606
10.1001/jamaophthalmol.2021.0606 · External reference
10.1001/jamaophthalmol.2023.5248
10.1001/jamaophthalmol.2023.5248 · External reference
10.1001/jama.282.15.1458
10.1001/jama.282.15.1458 · External reference
10.1001/jamaophthalmol.2022.1819
10.1001/jamaophthalmol.2022.1819 · External reference
10.1016/j.ophtha.2024.12.020
10.1016/j.ophtha.2024.12.020 · External reference
10.1136/bjo-2025-328196
10.1136/bjo-2025-328196 · External reference
10.1001/jamaophthalmol.2016.1669
10.1001/jamaophthalmol.2016.1669 · External reference
10.2147/opth.s100168
10.2147/opth.s100168 · External reference
